Moderna Inc. shares rose 7.84 percent in Friday trading

after the company announced that European regulators recommended approving its COVID-19 vaccine for teens as young as 12 years old. The recommendation was issued by the European Medicines Agency's Committee for Medicinal Products for Human Use; the final decision will be made by the European Commission. In the United States, Moderna's shot has not yet been approved for adolescent use. So far this year, the company's stock has risen 223.2 percent.